Commentary

Video

Dr Ye on the Safety and Efficacy of BL-B01D1 in Locally Advanced/Metastatic Urothelial Carcinoma

Dingwei Ye, MD, PhD, discusses the safety and efficacy outcomes of a clinical trial evaluating BL-B01D1 in locally advanced or metastatic urothelial carcinoma.

Dingwei Ye, MD, PhD, professor, director, the Multidisciplinary Team for Genitourinary (GU) Cancer, director, Fudan University Prostate Cancer Institute; president, GU Cancer Committee of Chinese Anti-Cancer Association, discussesthe safety and efficacy outcomes of a phase 1b/2 study (NCT05785039) evaluating the potential first-in-class antibody-drug conjugate (ADC) BL-B01D1 in patients with locally advanced or metastatic urothelial carcinoma.

Ye begins by noting that this ADC is comprised of an EGFR x HER3 bispecific antibody attached to a novel topoisomerase I inhibitor payload.

Early results from the investigation of BL-B01D1 were presented at the 2024 ESMO Congress. A total of 27 patients with locally advanced or metastatic urothelial carcinoma were enrolled onto the trial and were administered 2.2 mg of BL-B01D1 on days 1 and 8 of the trial, followed by once every 3 weeks thereafter.

The efficacy data were promising, Ye reports. The confirmed overall response rate (cORR) with BL- B01D1 was 33.3% (95% CI, 16.5%-54.0%) in the total population (n = 27). In patients who had receieved 1 prior line of chemotherapy (n = 12), the cORR was 75.0% (95% CI, 42.8%-94.5%), he adds. Additionally, the disease control rate (DCR) was 96.3% (95% CI, 81.0%-99.9%) in the total population and 100% (95% CI, 73.5%-100%) in those who had received priorchemotherapy.

The median duration of response (DOR) was not reached (NR; 95% CI, NR-NR) and the 6-month DOR was 100% (95% CI, 100%-100%) across both groups. Ye reports that the median progression-free survival (PFS) was not reached in either group; the 6-month PFS rate was 62.4% (95% CI, 62.4%, 32.2%-82.2%) in the total population and 100% (95% CI, 100%-100%) in the prior chemotherapy population.

No treatment-related deaths or interstitial lung disease events were reported, Ye continues, noting that the most common treatment-related adverse effects (TRAEs) were hematologic toxicities. Additionally, no new safety signals were observed with BL-B01D1, Ye concludes.

Related Videos
Yungan Tao, MD
Jared Weiss, MD
Sally Lau, MD
Hope S. Rugo, MD
Amrita Krishnan, MD, executive medical director, Hematology, director, Judy and Bernard Briskin Multiple Myeloma Center, professor, Department of Hematology & Hematopoietic Cell Transplantation, City of Hope
Idoroenyi Amanam, MD
Francisco Hernandez-Ilizaliturri, MD, professor, oncology, Department of Medicine—Lymphoma; director, Lymphoma Research, head, Lymphoma Translational Research Lab; associate professor, Department of Immunology, Roswell Park Comprehensive Cancer Center; clinical professor, Department of Medicine, Jacobs School of Medicine and Biomedical Sciences, University at Buffalo
Srikala Sridhar, MD, MSc, FRCPC
Andrea Wolf, MD, MPH
Suzanne Lentzsch, MD, PhD